🏛️ Verified NIH Record • Updated 2026-03-12

SNV4818 in Participants With Advanced Solid Tumors (NCT06736704)

A Phase 1/2, Open-Label Dose Escalation and Expansion Study of SNV4818 as Monotherapy or in Combination With Other Anticancer Agents in Participants With Advanced Solid Tumors

🟢 Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic Sponsor: Pikavation Therapeutics, Inc.

🩺 Plain-English Summary (8th-Grade Level)

This study is testing a new medicine, SNV4818, for people with advanced cancers. The researchers want to find out if SNV4818 is safe, well-tolerated, and effective in treating solid tumors. They are investigating different doses in order to find the safest and most effective one.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (4 items) and avoid the listed exclusions (6 items).

Location: The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate — Los Angeles, California

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Usually NOT eligible if any of the following apply:

  • Exclusion Criteria:
  • Diagnosis of a primary CNS malignancy
  • Active brain metastases or carcinomatous meningitis
  • Type 1 diabetes mellitus or uncontrolled type 2 diabetes mellitus
  • Inadequate organ function
  • Clinically significant ECG abnormalities, including QTcF ≥ 470 ms

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (12 Sites)

  • The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate — Los Angeles, California
  • Massachusetts General Hospital — Boston, Massachusetts
  • Thomas Jefferson University-Sidney Kimmel Cancer Center — Philadelphia, Pennsylvania
  • Sarah Cannon Research Institute — Nashville, Tennessee
  • The University of Texas M.D. Anderson Cancer Center — Houston, Texas
  • Chris O'Brien Lifehouse — Camperdown, New South Wales
  • Scientia Clinical Research — Randwick, New South Wales
  • Monash Health — Clayton, Victoria
  • Peter MacCallum Cancer Centre — Melbourne, Victoria
  • Linear Clinical Research — Nedlands, Western Australia
  • The Ottawa Hospital Cancer Centre — Ottawa, Ontario
  • University Health Network, Princess Margaret Cancer Centre — Toronto, Ontario

📞 Contact the Study Coordinator

Phone: (443) 764-9527

Email: rcasper@synnovationtx.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Advanced Solid Tumors

Explore by condition: All Advanced Solid Tumors clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Contact the study coordinator using the phone/email above.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗